You have read all your free articles, to continue reading subscribe to read the rest of this content.
AstraZeneca announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of saxa/dapa (saxagliptin and dapagliflozin) tablets for the treatment of adults with type-2 diabetes. The fixed-dose combAlready a subscriber Login You have read all your…
Targovax announced earlier this summer that its lead clinical candidate ONCOS-102 has received Fast Track designation in PD-1-refractory advanced melanoma from the US FDA. The US FDA has granted Fast Track designation to ONCOS-102 based on the current pre-clinical and clinical data package, incluAlready a subscriber Login You have read…
The two companies are now supplying Ximluci (ranibizumab biosimilar) in England via a National Health Service (NHS) England Framework Agreement. The partners announced in January 2023 that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) had granted a marketing authorization Already a subscriber Login You have read all your…
Alexion, AstraZeneca’s Rare Disease group, has entered into an exclusive global collaboration and licence agreement with Neurimmune for NI006, an investigational human monoclonal antibody currently in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). NI00Already a subscriber Login You have read all your free articles, to continue…
